Holdings: Inhibition of folate metabolism in chemotherapy

Inhibition of folate metabolism in chemotherapy: the origins and uses of co-trimoxazole

Saved in:

Bibliographic Details
Format:	Book
Language:	English
Published:	Berlin [u.a.] Springer 1983
Series:	Handbook of experimental pharmacology 64
Subjects:	Folic Acid Antimetabolites Sulfamethoxazole Pharmacodynamics Trimethoprim Antibiotica Antifoliques Cotrimoxazole - Effets physiologiques Farmacodynamica Foliumzuur Inhibitie Stofwisseling Sulfonamiden Co-trimoxazole > Physiological effect Folic Acid > metabolism Folic acid > Antagonists Sulfamethoxazole > pharmacology Trimethoprim > pharmacology Cotrimoxazol Folsäure Folate Chemotherapie
Online Access:	Inhaltsverzeichnis
Physical Description:	XXI, 457 S. Ill., graph. Darst.
ISBN:	3540117822 0387117822

Staff View

MARC


LEADER	00000nam a2200000 cb4500
001	BV000077338
003	DE-604
005	20150923
007	t
008	870612s1983 ad\|\| \|\|\|\| 00\|\|\| eng d
020			\|a 3540117822 \|9 3-540-11782-2
020			\|a 0387117822 \|9 0-387-11782-2
035			\|a (OCoLC)8667843
035			\|a (DE-599)BVBBV000077338
040			\|a DE-604 \|b ger \|e rakwb
041	0		\|a eng
049			\|a DE-12 \|a DE-19 \|a DE-355 \|a DE-210 \|a DE-20 \|a DE-11 \|a DE-188 \|a DE-578
050		0	\|a QP905
050		0	\|a RM666.C567
082	0		\|a 615/.7 \|2 19
082	0		\|a 615/.1 \|2 19
084			\|a XI 1701 \|0 (DE-625)152977:12907 \|2 rvk
084			\|a QV 4 \|2 nlm
245	1	0	\|a Inhibition of folate metabolism in chemotherapy \|b the origins and uses of co-trimoxazole \|c contributors J. F. Acar ... Ed. G. H. Hitchings
264		1	\|a Berlin [u.a.] \|b Springer \|c 1983
300			\|a XXI, 457 S. \|b Ill., graph. Darst.
336			\|b txt \|2 rdacontent
337			\|b n \|2 rdamedia
338			\|b nc \|2 rdacarrier
490	1		\|a Handbook of experimental pharmacology \|v 64
650		7	\|a Folic Acid \|2 cabt
650		7	\|a Antimetabolites \|2 cabt
650		7	\|a Sulfamethoxazole \|2 cabt
650		7	\|a Pharmacodynamics \|2 cabt
650		7	\|a Trimethoprim \|2 cabt
650		7	\|a Antibiotica \|2 gtt
650		4	\|a Antifoliques
650		4	\|a Cotrimoxazole - Effets physiologiques
650		7	\|a Farmacodynamica \|2 gtt
650		7	\|a Foliumzuur \|2 gtt
650		7	\|a Inhibitie \|2 gtt
650		7	\|a Stofwisseling \|2 gtt
650		7	\|a Sulfonamiden \|2 gtt
650		7	\|a Trimethoprim \|2 gtt
650		4	\|a Co-trimoxazole \|x Physiological effect
650		4	\|a Folic Acid \|x metabolism
650		4	\|a Folic acid \|x Antagonists
650		4	\|a Sulfamethoxazole \|x pharmacology
650		4	\|a Trimethoprim \|x pharmacology
650	0	7	\|a Cotrimoxazol \|0 (DE-588)4148337-6 \|2 gnd \|9 rswk-swf
650	0	7	\|a Folsäure \|0 (DE-588)4121288-5 \|2 gnd \|9 rswk-swf
650	0	7	\|a Folate \|0 (DE-588)4154952-1 \|2 gnd \|9 rswk-swf
650	0	7	\|a Chemotherapie \|0 (DE-588)4127083-6 \|2 gnd \|9 rswk-swf
689	0	0	\|a Cotrimoxazol \|0 (DE-588)4148337-6 \|D s
689	0	1	\|a Chemotherapie \|0 (DE-588)4127083-6 \|D s
689	0		\|5 DE-604
689	1	0	\|a Folsäure \|0 (DE-588)4121288-5 \|D s
689	1	1	\|a Chemotherapie \|0 (DE-588)4127083-6 \|D s
689	1		\|5 DE-604
689	2	0	\|a Folate \|0 (DE-588)4154952-1 \|D s
689	2	1	\|a Chemotherapie \|0 (DE-588)4127083-6 \|D s
689	2		\|5 DE-604
700	1		\|a Hitchings, George H. \|d 1905-1998 \|e Sonstige \|0 (DE-588)110178602 \|4 oth
700	1		\|a Acar, Jacques F. \|d 1931-2020 \|e Sonstige \|0 (DE-588)171944666 \|4 oth
830		0	\|a Handbook of experimental pharmacology \|v 64 \|w (DE-604)BV002390716 \|9 64
856	4	2	\|m GBV Datenaustausch \|q application/pdf \|u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000035270&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA \|3 Inhaltsverzeichnis
999			\|a oai:aleph.bib-bvb.de:BVB01-000035270

Record in the Search Index

_version_	1804114532434444288
adam_text	1 -- 26 0 2 - -&% INHIBITION OF FOLATE METABOLISM IN CHEMOTHERAPY THE ORIGINS AND USES OF CO-TRIMOXAZOLE CONTRIBUTORS J. F. ACAR * N. ANAND * D. W BARRY * R. E. BLACK * J. J. BURCHALL S. R. M. BUSHBY * M. L. CLEMENTS * A. D. DAYAN R. E. DESJARDINS * F. W. GOLDSTEIN * L.T. GUTMAN * I. HANSEN G. H. HITCHINGS * D. T. D. HUGHES * G. T. KEUSCH * D. H. LAWSON M. M. LEVINE * F O GRADY * K. H. PATTISHALL * I. M. ROLLO B. ROTH * J. K. SEYDEL * C. W SIGEL * T. A. STAMEY * W E. STAMM C. M. WILFERT * G. P. WORMSER EDITOR G. H. HITCHINGS UNIVERSITATS- BIBLIOTHEK SPRINGER-VERLAG BERLIN HEIDELBERG NEW YORK 1983 CONTENTS TRIMETHOPRIM/SULFAMETHOXAZOLE: AN OVERVIEW. G. P. WORMSER AND G. T. KEUSCH. WITH 1 FIGURE A. INTRODUCTION 1 B. MECHANISMS OF ACTION 1 C. RESISTANCE 3 I. CHROMOSOME-MEDIATED RESISTANCE 3 II. PLASMID-MEDIATED RESISTANCE 4 III. THYMIDINE DEPENDENCE 4 D. CLINICAL USE OF TMP/SMX 5 I. APPROVED INDICATIONS IN THE UNITED STATES 5 II. OTHER IMPORTANT USES 5 E. USE OF TMP OR SMX AS SINGLE AGENTS 6 F. ADVERSE EFFECTS 6 G. SUMMARY 7 REFERENCES 7 PHARMACOLOGY AND BIOCHEMISTRY CHAPTER 1 - FUNCTIONS OF TETRAHY DROFOLATE AND THE ROLE OF DIHYDROFOLATE REDUCTASE IN CELLULAR METABOLISM. G. H. HITCHINGS. WITH 6 FIGURES A. GENERAL 11 B. OCCURRENCE OF FOLATES 11 C. FUNCTIONS OF TETRAHYDROFOLATE: COFACTORS 12 I. FORMATE AND EQUIVALENTS 12 1. PURINE BIOSYNTHESIS 13 II. FORMALDEHYDE EQUIVALENTS, HYDROXYMETHYL, AND METHYL DERIVATIVES 14 1. METHIONINE BIOSYNTHESIS 14 2. THYMIDYLATE SYNTHESIS 15 3. VITAMINS AND OTHER METABOLITES 16 D. ORIGINS OF CELLULAR FOLATES 16 E. TRANSPORT SYSTEMS 17 I. SELECTIVE RESCUE . 18 F. MECHANISM OF ACTION OF TMP/SMX 18 I. THYMINELESS DEATH 20 X CONTENTS G. SUMMARY 20 REFERENCES 20 CHAPTER 2 SULFONAMIDES: STRUCTURE-ACTIVITY RELATIONSHIPS AND MECHANISM OF ACTION. N. ANAND. WITH 1 FIGURE A. INTRODUCTION 25 B. DEVELOPMENT OF SULFONAMIDES AND SULFONES 26 I. SULFONAMIDES 26 II. SULFONES 29 III. ANTIMICROBIAL SPECTRUM 30 C. STRUCTURE AND BIOLOGICAL ACTIVITY 31 I. STRUCTURE-ACTIVITY RELATIONSHIP 31 II. PHYSICOCHEMICAL PROPERTIES AND ANTIMICROBIAL ACTIVITY 32 1. WATER SOLUBILITY 34 2. LIPID SOLUBILITY 36 3. PROTEIN BINDING 36 III. PHARMACOKINETICS AND METABOLISM 37 1. SULFONAMIDES 37 2. SULFONES 38 IV. HALF-LIFE 38 D. MODE OF ANTIMICROBIAL ACTION 39 I. FOLIC ACID METABOLISM 39 II. ACTION OF SULFONAMIDES AND SULFONES 41 1. SELECTIVITY OF ACTION 44 III. SYNERGISM WITH DIHYDROFOLATE REDUCTASE INHIBITORS 45 IV. DRUG RESISTANCE 45 E. PRESENT STATUS IN THERAPEUTICS 46 REFERENCES 47 CHAPTER 3 DIHYDROFOLATE REDUCTASE. J. J. BURCHALL A. INTRODUCTION 55 B. ASSAY AND KINETIC STUDIES 56 C. MECHANISM OF ACTION 57 D. BASIS OF SELECTIVITY 58 I. KINETIC STUDIES 58 II. INHIBITOR BINDING ANALYSIS 59 III. ENZYME CONFORMATION AND COOPERATIVITY 62 IV. AMINO ACID SEQUENCES 63 V. THREE-DIMENSIONAL STRUCTURES OF DHFR 65 E. PLASMID-CODED REDUCTASES 68 F. GENETICS OF DHFR 69 REFERENCES 70 CONTENTS XI CHAPTER 4 ANTIBACTERIAL ACTIVITY. S. R. M. BUSHBY. WITH 4 FIGURES A. INTRODUCTION 75 B. IN VITRO ACTIVITY 75 I. EFFECTS OF MEDIUM AND SIZE OF INOCULUM 75 II. BACTERIOSTATIC ACTIVITY 77 III. BACTERICIDAL ACTIVITY 80 IV. DEMONSTRATION OF SYNERGY 80 C. SYNERGY AND SULFONAMIDE-RESISTANT STRAINS 86 D. REVERSAL OF ACTIVITY OF TMP 87 E. DEVELOPMENT OF RESISTANCE 87 F. SPECTRUM OF ACTIVITY OF TMP/SMX 90 G. CHOICE OF SULFONAMIDE 92 H. 2,4-DIAMINOPYRIMIDINES AS SINGLE AGENTS 94 J. SUSCEPTIBILITY TESTING 96 REFERENCES 99 CHAPTER 5 SELECTIVE INHIBITORS OF BACTERIAL DIHYDROFOLATE REDUCTASE: STRUCTURE-ACTIVITY RELATIONSHIPS. B. ROTH. WITH 2 FIGURES A. INTRODUCTION 107 B. HISTORICAL PERSPECTIVE 109 C. SOME GENERAL REQUIREMENTS FOR DHFR INHIBITION AND ANTIBACTERIAL ACTIVITY ILL D. INHIBITORS OF SPECIFIC DHFRS ILL I. THE 5-PHENYL DERIVATIVES AND RELATED COMPOUNDS ILL II. 5-BENZYL-2,4-DIAMINOPYRIMIDINES AND CLOSE RELATIVES 112 1. THE 6-UNSUBSTITUTED DERIVATIVES .112 2. 6-SUBSTITUTED DERIVATIVES 115 3. SUBSTITUTION OF A HETEROCYCLIC RING FOR THE BENZENE MOIETY . . 116 4. VARIATIONS IN THE BRIDGE BETWEEN THE PYRIMIDINE AND BENZENE RINGS 116 III. THE 1,2-DIHYDRO-1,3,5-TRIAZINES 117 IV. BICYCLIC ANALOGS OF THE DIAMINOPYRIMIDINES 117 E. DISCUSSION 118 F. CONCLUSION 121 REFERENCES 122 CHAPTER 6 KINETICS OF ANTIBACTERIAL EFFECTS. J. K. SEYDEL. WITH 19 FIGURES A. INTRODUCTION: BACTERIAL GROWTH KINETICS IN THE PRESENCE OF FOLATE INHIBITORS 129 B. SULFONAMIDES (SYNTHETASE INHIBITORS) 131 I. EFFECT OF SULFONAMIDES ON GENERATION RATES OF E. COLI 131 XII CONTENTS C. TRIMETHOPRIM (TMP): DIHYDROFOLATE REDUCTASE INHIBITOR 133 I. EFFECT OF TMP ON GENERATION RATES OF E. COLI 133 II. INFLUENCE OF TMP CONCENTRATION AND INOCULUM SIZE ON THE BACTERICIDAL EFFECT OF TMP 135 III. REVERSIBILITY OF TMP ACTION 137 IV. INFLUENCE OF CULTURE BROTH CONSTITUENTS ON BIPHASIC INHIBITION . .138 V. DEVELOPMENT OF RESISTANCE AGAINST DIHYDROFOLIC ACID REDUCTASE INHIBITORS 142 D. COMBINED ACTION OF SULFONAMIDES AND TRIMETHOPRIM (FOLATE INHIBITORS) 143 I. EFFECT OF TMP/SMX ON GENERATION RATES OF E. COLI 143 II. INFLUENCE OF INHIBITORY POWER AND CONCENTRATION OF SULFONAMIDES OR SULFONES ON THE DEGREE OF SYNERGISM 145 III. INFLUENCE OF INHIBITORY POWER OF TMP DERIVATIVES ON THE DEGREE OF SYNERGISM AND MAXIMAL POSSIBLE EFFECT 151 IV. SELECTION CRITERIA FOR COMBINATION OF TMP AND TMP DERIVATIVES WITH SULFONAMIDES 151 V. MODE OF ACTION OF SULFONAMIDES, TMP, AND THEIR COMBINATIONS 155 1. SULFONAMIDES 155 2. TMP 156 3. COMBINATIONS OF SULFONAMIDES AND TMP 158 REFERENCES 158 CHAPTER 7 DISPOSITION AND METABOLISM OF TRIMETHOPRIM, TETROXOPRIM, SULFAMETHOXAZOLE, AND SULFADIAZINE. C. W. SIGEL. WITH 4 FIGURES A. INTRODUCTION 163 B. DRUG DISPOSITION 163 I. DRUG ABSORPTION 163 II. DISTRIBUTION INTO BIOLOGIC FLUIDS AND TISSUES . . . . . . . . . . 164 1. PHYSICOCHEMICAL PROPERTIES THAT INFLUENCE DISTRIBUTIONS . . . .164 2. RELATIONSHIP BETWEEN PLASMA AND TISSUE CONCENTRATIONS . . .164 III. EXCRETION 168 IV. METABOLISM 169 1. TRIMETHOPRIM 169 2. TETROXOPRIM 173 3. SULFAMETHOXAZOLE 174 4. SULFADIAZINE 175 C. DRUG ASSAY METHODS 177 I. TRIMETHOPRIM AND RELATED BENZYLPYRIMIDINES 177 1. SPECTROFLUOROMETRIC METHODS 177 2. QUANTITATIVE THIN LAYER CHROMATOGRAPHY 177 3. HIGH PRESSURE LIQUID CHROMATOGRAPHIC METHODS 178 4. GAS-LIQUID CHROMATOGRAPHIC ANALYSIS 178 5. MICROBIOLOGIC PROCEDURES 178 6. OTHER METHODS 179 CONTENTS XIII II. SULFONAMIDES 1. SPECTROPHOTOMETRIC METHODS 179 2. QUANTITATIVE THIN LAYER CHROMATOGRAPHY 179 3. HIGH PRESSURE LIQUID CHROMATOGRAPHY METHODS 180 D. CONCLUSION 180 REFERENCES 180 CHAPTER 8 PRECLINICAL TOXICITY TESTING OF CO-TRIMOXAZOLE AND OTHER TRIMETHOPRIM/ SULFONAMIDE COMBINATIONS. A. D. DAYAN A. INTRODUCTION 185 B. GENERAL PHARMACODYNAMIC ACTIONS 185 I. TRIMETHOPRIM 185 II. TRIMETHOPRIM AND SULFAMOXOLE 186 C. ACUTE TOXICITY 186 I. TRIMETHOPRIM, SULFAMETHOXAZOLE, AND CO-TRIMOXAZOLE 186 II. TRIMETHOPRIM AND SULFAMETHOXYPYRIDAZINE 187 D. SUBACUTE AND CHRONIC TOXICITY TESTS 188 I. TRIMETHOPRIM 188 1. RATS 188 2. MONKEYS 189 3. OTHER SPECIES 190 II. TRIMETHOPRIM AND SULFAMETHOXAZOLE 190 1. RATS 190 .2. RABBITS 192 3. MONKEYS 192 E. COMBINATIONS OF TRIMETHOPRIM AND OTHER SULFONAMIDES 192 I. TRIMETHOPRIM AND SULFAFURAZOLE . . 192 II. TRIMETHOPRIM AND SULFADIAZINE .192 III. TRIMETHOPRIM AND SULFAMOXOLE 193 IV. TRIMETHOPRIM AND SULFAMETHOXYPYRAZINE 194 F. SPECIAL STUDIES OF THE THYROID AND TRIMETHOPRIM/SULFONAMIDE COMBINATIONS 194 G. OTHER ACTIONS OF TRIMETHOPRIM ALONE OR COMBINED WITH SULFONAMIDES 195 I. CO-TRIMOXAZOLE AND IMMUNOSUPPRESSION 195 II. LOCAL EFFECTS OF INTRAMUSCULAR INJECTION OF TRIMETHOPRIM AND VARIOUS SULFONAMIDES 195 III. CO-TRIMOXAZOLE AND RENAL FAILURE 196 H. REPRODUCTIVE TOXICOLOGY 196 I. FETAL TOXICITY TESTS 196 1. RATS 196 2. RABBITS 198 II. FERTILITY TESTS 198 1. RATS 198 2. RABBITS 199 XIV CONTENTS 3. HAMSTERS 199 4. CONCLUSIONS 199 5. OTHER RELATED INFORMATION 200 III. REPRODUCTIVE TOXICITY OF TRIMETHOPRIM COMBINED WITH OTHER SULFONAMIDES 200 1. TRIMETHOPRIM AND SULFAMOXOLE 200 2. TRIMETHOPRIM AND SULFAMETHOXYPYRAZINE 201 J. MUTAGENICITY 201 I. POINT MUTATION TESTS IN BACTERIA 201 II. HUMAN CYTOGENETIC STUDIES 201 REFERENCES 202 CLINICAL PHARMACOLOGY CHAPTER 9 ADVERSE EFFECT OF CO-TRIMOXAZOLE. D. H. LAWSON. WITH 5 FIGURES A. INTRODUCTION 207 B. GASTROINTESTINAL DISORDERS 209 I. UPPER GASTROINTESTINAL SYMPTOMS 209 II. LOWER GASTROINTESTINAL SYMPTOMS 210 C. SKIN DISORDERS 210 I. TOXIC ERYTHEMA 214 II. OTHER SKIN REACTIONS 215 III. SULFAMETHOXAZOLE OR TRIMETHOPRIM? 216 D. RENAL DISORDERS 216 E. HAEMATOLOGICAL DISORDERS 218 I. FOLIC ACID DEFICIENCY . . . . 218 II. LEUCOPENIA/AGRANULOCYTOSIS 218 III. THROMBOCYTOPENIA 220 IV. HAEMOLYTIC ANAEMIA 220 F. JAUNDICE 221 I. LIVER DAMAGE 221 II. HYPERBILIRUBINAEMIA OF THE NEWBORN 221 G. PREGNANCY 221 H. MISCELLANEOUS 222 J. DRUG INTERACTIONS 222 I. PYRIMETHAMINE 222 II. AZATHIOPRINE 223 III. WARFARIN 223 IV. PHENYTOIN 223 V. HYPOGLYCAEMIC AGENTS 224 K. CONCLUSIONS 224 REFERENCES 224 CONTENTS XV CHAPTER 10 CLINICAL PHARMACOKINETICS OF CO-TRIMOXAZOLE. I. HANSEN A. INTRODUCTION 229 B. ABSORPTION AND BIOLOGIC HALF-LIVES 229 C. DISTRIBUTION 231 I. PLASMA 231 II. CEREBROSPINAL FLUID 232 III. AQUEOUS HUMOR 232 IV. BREAST MILK 232 V. PROSTATIC AND SEMINAL MATERIAL 233 VI. VAGINAL FLUID 233 VII. PLACENTAL AND FETAL MATERIAL 233 VIII. BILE FLUID 233 IX. ERYTHROCYTES 234 X. BONE 234 XI. OTHER TISSUES AND ORGANS 234 D. METABOLISM 234 E. ELIMINATION 235 F. INTERACTIONS 238 REFERENCES 238 CHAPTER 11 RESISTANCE: GENETICS AND MEDICAL IMPLICATIONS: J. F. ACAR AND F. W. GOLDSTEIN A. INTRODUCTION 243 B. RESISTANCE TO SULFONAMIDES 243 I. DEFINITION 243 II. NATURAL RESISTANCE 243 III. ACQUIRED RESISTANCE 243 C. RESISTANCE TO TRIMETHOPRIM . 243 I. DEFINITION 243 II. NATURAL RESISTANCE 244 III. ACQUIRED RESISTANCE 244 D. MECHANISMS OF ACQUIRED RESISTANCE TO SULFONAMIDES 244 I. RESULTS OF MUTATIONS 244 1. DECREASED PERMEABILITY 244 2. HYPERPRODUCTION OF P-AMINOBENZOIC ACID 244 3. ALTERED DIHYDROPTEROATE SYNTHASE 245 II. ACQUISITION OF R FACTORS 245 E. MECHANISM OF ACQUIRED RESISTANCE TO TRIMETHOPRIM 245 I. BY MUTATION 245 1. THYMINELESS ORGANISMS 245 2. MODIFICATION OF DIHYDROFOLATE REDUCTASE 246 II. PLASMID-MEDIATED RESISTANCE 247 1. TRANSFERABLE 248 2. NONTRANSFERABLE 248 XVI CONTENTS F. MEDICAL IMPLICATIONS 248 I. SULFONAMIDE-RESISTANT STRAINS 248 II. SULFONAMIDE-SENSITIVE, TRIMETHOPRIM-RESISTANT STRAINS 249 III. EMERGENCE OF RESISTANT STRAINS DURING THERAPY 249 G. EPIDEMIOLOGIC OVERVIEW OF RESISTANCE TO TRIMETHOPRIM 250 I. GRAM-POSITIVE BACTERIA 250 II. GRAM-NEGATIVE BACTERIA 250 REFERENCES 252 CLINICAL STUDIES CHAPTER 12 TRIMETHOPRIM ALONE: CLINICAL USES. D. W. BARRY AND K. H. PATTISHALL. WITH 2 FIGURES A. INTRODUCTION 261 B. MICROBIOLOGIC AND PHARMACOKINETIC PROPERTIES 261 C. RELATION OF SENSITIVITIES AND PHARMACOKINETICS TO THERAPY OF URINARY TRACT INFECTIONS 264 I. GENERAL 264 II. UNCOMPLICATED URINARY TRACT INFECTIONS 267 III. COMPLICATED URINARY TRACT INFECTIONS 271 D. PROPHYLAXIS 273 I. RECURRING URINARY INFECTION IN WOMEN AND CHILDREN 273 II. IMMUNOSUPPRESSED PATIENTS 275 E. ADVERSE REACTIONS AND SAFETY 276 I. GENERAL 276 II. DERMATOLOGIC 277 III. GASTROINTESTINAL , 280 IV. HEMATOLOGIC 280 F. BACTERIAL RESISTANCE 281 I. GENERAL 281 II. FINNISH EXPERIENCE 282 III. EFFECT ON FECAL FLORA 286 G. CONCLUSION 286 REFERENCES 287 CHAPTER 13 INHIBITORS OF DIHYDROFOLATE REDUCTASE AS ANTIPROTOZOAL AGENTS. I. M. ROLLO. WITH 4 FIGURES A. INTRODUCTION 293 B. POINTS OF POSSIBLE THERAPEUTIC ATTACK 295 CONTENTS XVII C. ANTIMALARIAL THERAPEUTICS 296 I. EARLY TRIALS 297 II. CLINICAL CURE WITH PYRIMETHAMINE 298 III. CAUSAL PROPHYLAXIS 299 IV. SUPPRESSION AND MASS PROPHYLAXIS 300 V. GAMETOCYTICIDAL EFFECTS 301 VI. RADICAL CURE 302 VII. DRUG RESISTANCE 303 VIII. COMBINATION WITH SULFONAMIDES AND SULFONES 303 1. SUPPRESSIVE AND CLINICAL CURE 303 2. EFFECT ON OTHER SPOROZOA 305 REFERENCES 306 CHAPTER 14 PEDIATRIC USES OF SULFONAMIDES, TRIMETHOPRIM, AND THE COMBINATION. L. T. GUTMAN AND C. M. WILFERT A. INTRODUCTION 309 B. HEMOPHILUS INFLUENZAE INFECTIONS 309 I. OTITIS MEDIA 310 1. ACUTE 310 2. SEROUS AND CHRONIC 311 II. SINUSITIS 311 III. PROPHYLAXIS TO PREVENT SECONDARY INFECTION 312 C. MENINGITIS 314 D. URINARY TRACT INFECTIONS 315 I. ACUTE 315 II. STRUCTURAL DEFECTS OF THE URINARY SYSTEM . 315 III. PREVENTION .315 IV. THERAPY OF PERIURETHRAL AND RECTAL FLORA .316 V. CHLAMYDIAL INFECTIONS 316 E. PNEUMOCYSTIS CARINII PNEUMONIA 318 I. THERAPY 318 II. PREVENTION 319 F. ENTERIC DISEASES 320 I. SALMONELLOSIS 320 II. SHIGELLOSIS 321 III. YERSINIA INFECTIONS 322 1. ACUTE ENTERITIS 323 2. CHRONIC ENTERITIS 323 3. MESENTERIC ADENITIS 323 G. MISCELLANEOUS CONDITIONS 324 I. CHRONIC GRANULOMATOUS DISEASE 324 II. OSTEOMYELITIS 324 III. ASCENDING CHOLANGITIS 324 REFERENCES 325 XVIII CONTENTS CHAPTER 15 USE OF CO-TRIMOXAZOLE IN URINARY TRACT INFECTION. F. O GRADY. WITH 2 FIGURES A. INTRODUCTION 331 B. CO-TRIMOXAZOLE IN ACUTE URINARY TRACT INFECTION 331 I. EPIDEMIOLOGY OF RESISTANCE 332 1. TYPES OF RESISTANCE 332 II. EFFECTS OF CARRIAGE SITES 333 1. EFFECT ON GUT FLORA 333 2. EFFECT ON URETHRAL COLONISATION 334 III. OVERTREATMENT 334 C. CONTROL OF RECURRENT INFECTION 335 D. ROLE OF THE COMBINATION 337 I. CONTRASTING EFFECTS OF TRIMETHOPRIM AND SULFONAMIDE IN THE URINE 337 II. TOXICITY 339 REFERENCES 339 CHAPTER 16 TREATMENT OF GENITAL INFECTIONS WITH TRIMETHOPRIM, SULFONAMIDES, AND COMBINATIONS. W. E. STAMM A. INTRODUCTION 343 B. TREATMENT OF GONORRHEA WITH TRIMETHOPRIM/SULFAMETHOXAZOLE . . . . 343 I. UNCOMPLICATED ANOGENITAL INFECTION 343 II. RECTAL INFECTION 348 III. PHARYNGEAL INFECTION 348 IV. IN VITRO STUDIES AND TREATMENT OF GONORRHEA WITH TRIMETHOPRIM/ SULFAMETHOXAZOLE 348 C. INFECTIONS DUE TO CHLAMYDIA TRACHOMATIS 350 I. POSTGONOCOCCAL URETHRITIS 350 II. NONGONOCOCCAL URETHRITIS 351 III. LYMPHOGRANULOMA VENEREUM 352 D. CHANCROID 352 E. SYPHILIS 354 REFERENCES 354 CHAPTER 17 TREATMENT OF ENTERIC INFECTIONS AND COMBINATIONS. M. L. CLEMENTS, R. E. BLACK, AND M. M. LEVINE A. ESCHERICHIA COLI DIARRHEA 357 I. INTRODUCTION 357 II. TRIMETHOPRIM/SULFAMETHOXAZOLE TREATMENT OF E. COLI DIARRHEA . .357 1. IN VITRO STUDIES 357 2. CLINICAL STUDIES 358 III. SUMMARY 358 CONTENTS XIX B. ISOSPORA BELLI INFECTIONS 358 I. INTRODUCTION 358 II. TRIMETHOPRIM/SULFAMETHOXAZOLE TREATMENT OF AN ISOSPORA BELLI INFECTION 359 C. SALMONELLA INFECTIONS 359 I. INTRODUCTION 359 1. TYPHOIDAL AND PARATYPHOIDAL SALMONELLA INFECTIONS 359 2. NON-TYPHOIDAL SALMONELLA INFECTIONS 360 II. TRIMETHOPRIM/SULFAMETHOXAZOLE IN THE TREATMENT OF SALMONELLA TYPHI INFECTIONS 361 1. THERAPEUTIC STUDIES IN ANTIBIOTIC-SENSITIVE S. TYPHI INFECTIONS . 361 2. STUDIES IN INFECTIONS DUE TO CHLORAMPHENICOL-RESISTANT S. TYPHI STRAINS 363 3. TRIMETHOPRIM/SULFAMETHOXAZOLE TREATMENT OF TYPHOID CARRIERS 364 4. ADVERSE EFFECTS 365 5. SUMMARY 365 III. TRIMETHOPRIM ALONE IN TREATMENT OF ENTERIC FEVER 366 IV. TRIMETHOPRIM/SULFAMETHOXAZOLE THERAPY IN NON-TYPHOIDAL SALMONELLOSIS 366 1. IN VITRO STUDIES 366 2. CLINICAL STUDIES 367 3. SUMMARY 368 D. SHIGELLA 368 I. INTRODUCTION 368 II. TRIMETHOPRIM/SULFAMETHOXAZOLE TREATMENT IN SHIGELLOSIS . . . . 369 1. IN VITRO STUDIES 369 2. CLINICAL STUDIES 370 3. SUMMARY 371 E. VIBRIO CHOLERAE INFECTIONS 371 I. INTRODUCTION : . 371 II. TRIMETHOPRIM/SULFAMETHOXAZOLE TREATMENT IN CHOLERA . . . . . 372 1. IN VITRO STUDIES .372 2. CLINICAL STUDIES 372 3. SUMMARY 373 F. YERSINIA ENTEROCOLITICA INFECTIONS 373 I. INTRODUCTION 373 II. TRIMETHOPRIM/SULFAMETHOXAZOLE AND YERSINIA ENTEROCOLITICA . . . 374 1. IN VITRO STUDIES 374 2. CLINICAL REPORT 375 3. SUMMARY 375 REFERENCES 375 CHAPTER 18 PROSTATITIS. T. A. STAMEY. WITH 1 FIGURE A. INTRODUCTION 379 B. CLASSIFICATION AND DESCRIPTION OF PATIENT CATEGORIES 379 XX CONTENTS C. ACUTE AND CHRONIC BACTERIAL PROSTATITIS 382 I. DIAGNOSIS 382 II. PATHOLOGY 384 III. PROSTATIC IMMUNOGLOBULINS 384 IV. THE ANTIBACTERIAL FACTOR IN PROSTATIC FLUID 385 V. TREATMENT 386 D. NONBACTERIAL PROSTATITIS 390 REFERENCES 392 CHAPTER 19 CO-TRIMOXAZOLE IN CHEST INFECTIONS INCLUDING ITS LONG-TERM USE IN CHEST DISEASE. D. T. D. HUGHES A. INTRODUCTION 397 B. EXACERBATIONS OF CHRONIC BRONCHITIS 397 I. LEVELS OF TWO COMPONENTS IN SPUTUM 399 II. COMPARATIVE TRIALS 400 C. OTHER ACUTE CONDITIONS 402 I. PNEUMOCYSTIS CARINII PNEUMONIA 403 D. LONG-TERM TREATMENT 404 E. PARENTERAL TMP/SMX 406 F. ALTERNATIVE DRUGS 406 G. TRIMETHOPRIM ALONE 407 H. FUTURE DEVELOPMENTS 408 REFERENCES 409 CHAPTER 20 TREATMENT OF MISCELLANEOUS AND UNUSUAL INFECTIONS WITH TRIMETHOPRIM AND TRIMETHOPRIM/SULFONAMIDE COMBINATIONS. R. E. DESJARDINS A. INTRODUCTION 411 B. BRUCELLOSIS 411 C. TOXOPLASMOSIS 414 D. NOCARDIOSIS 417 E. ATYPICAL MYCOBACTERIA 421 F. MYCOSES 422 I. HISTOPLASMOSIS 422 II. PARACOCCIDIOIDOMYCOSIS 423 III. PHYCOMYCOSIS 424 IV. CHROMOMYCOSIS 425 G. PSEUDOMONAS INFECTIONS 425 I. PSEUDOMONAS PSEUDOMALLEI 426 II. PSEUDOMONAS CEPACIA AND PSEUDOMONAS MALTOPHILIA 427 H. OTHER INFECTIONS 428 I. BUBONIC PLAGUE 429 CONTENTS XXI II. RICKETTSIOSIS 429 1. BOUTONNEUSE FEVER 430 2. Q FEVER 430 III. LEGIONELLA PNEUMOPHILA AND PITTSBURGH PNEUMONIA AGENT INFECTIONS 430 IV. ISOSPORA BELLI INFECTIONS 430 V. MALAKOPLAKIA 431 VI. PEDICULOSIS 431 REFERENCES 431 SUBJECT INDEX 441
any_adam_object	1
author_GND	(DE-588)110178602 (DE-588)171944666
building	Verbundindex
bvnumber	BV000077338
callnumber-first	Q - Science
callnumber-label	QP905
callnumber-raw	QP905 RM666.C567
callnumber-search	QP905 RM666.C567
callnumber-sort	QP 3905
callnumber-subject	QP - Physiology
classification_rvk	XI 1701
ctrlnum	(OCoLC)8667843 (DE-599)BVBBV000077338
dewey-full	615/.7 615/.1
dewey-hundreds	600 - Technology (Applied sciences)
dewey-ones	615 - Pharmacology and therapeutics
dewey-raw	615/.7 615/.1
dewey-search	615/.7 615/.1
dewey-sort	3615 17
dewey-tens	610 - Medicine and health
discipline	Medizin
format	Book
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02905nam a2200769 cb4500</leader><controlfield tag="001">BV000077338</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20150923 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">870612s1983 ad\|\| \|\|\|\| 00\|\|\| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3540117822</subfield><subfield code="9">3-540-11782-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0387117822</subfield><subfield code="9">0-387-11782-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)8667843</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV000077338</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-210</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-11</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QP905</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM666.C567</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.7</subfield><subfield code="2">19</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.1</subfield><subfield code="2">19</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 1701</subfield><subfield code="0">(DE-625)152977:12907</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QV 4</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Inhibition of folate metabolism in chemotherapy</subfield><subfield code="b">the origins and uses of co-trimoxazole</subfield><subfield code="c">contributors J. F. Acar ... Ed. G. H. Hitchings</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin [u.a.]</subfield><subfield code="b">Springer</subfield><subfield code="c">1983</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXI, 457 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Handbook of experimental pharmacology</subfield><subfield code="v">64</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Folic Acid</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antimetabolites</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sulfamethoxazole</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmacodynamics</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Trimethoprim</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antibiotica</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antifoliques</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cotrimoxazole - Effets physiologiques</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Farmacodynamica</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Foliumzuur</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Inhibitie</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Stofwisseling</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sulfonamiden</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Trimethoprim</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Co-trimoxazole</subfield><subfield code="x">Physiological effect</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Folic Acid</subfield><subfield code="x">metabolism</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Folic acid</subfield><subfield code="x">Antagonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sulfamethoxazole</subfield><subfield code="x">pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Trimethoprim</subfield><subfield code="x">pharmacology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cotrimoxazol</subfield><subfield code="0">(DE-588)4148337-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Folsäure</subfield><subfield code="0">(DE-588)4121288-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Folate</subfield><subfield code="0">(DE-588)4154952-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Cotrimoxazol</subfield><subfield code="0">(DE-588)4148337-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Folsäure</subfield><subfield code="0">(DE-588)4121288-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Folate</subfield><subfield code="0">(DE-588)4154952-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hitchings, George H.</subfield><subfield code="d">1905-1998</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)110178602</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Acar, Jacques F.</subfield><subfield code="d">1931-2020</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)171944666</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Handbook of experimental pharmacology</subfield><subfield code="v">64</subfield><subfield code="w">(DE-604)BV002390716</subfield><subfield code="9">64</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000035270&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-000035270</subfield></datafield></record></collection>
id	DE-604.BV000077338
illustrated	Illustrated
indexdate	2024-07-09T15:08:13Z
institution	BVB
isbn	3540117822 0387117822
language	English
oai_aleph_id	oai:aleph.bib-bvb.de:BVB01-000035270
oclc_num	8667843
open_access_boolean
owner	DE-12 DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-210 DE-20 DE-11 DE-188 DE-578
owner_facet	DE-12 DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-210 DE-20 DE-11 DE-188 DE-578
physical	XXI, 457 S. Ill., graph. Darst.
publishDate	1983
publishDateSearch	1983
publishDateSort	1983
publisher	Springer
record_format	marc
series	Handbook of experimental pharmacology
series2	Handbook of experimental pharmacology
spelling	Inhibition of folate metabolism in chemotherapy the origins and uses of co-trimoxazole contributors J. F. Acar ... Ed. G. H. Hitchings Berlin [u.a.] Springer 1983 XXI, 457 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Handbook of experimental pharmacology 64 Folic Acid cabt Antimetabolites cabt Sulfamethoxazole cabt Pharmacodynamics cabt Trimethoprim cabt Antibiotica gtt Antifoliques Cotrimoxazole - Effets physiologiques Farmacodynamica gtt Foliumzuur gtt Inhibitie gtt Stofwisseling gtt Sulfonamiden gtt Trimethoprim gtt Co-trimoxazole Physiological effect Folic Acid metabolism Folic acid Antagonists Sulfamethoxazole pharmacology Trimethoprim pharmacology Cotrimoxazol (DE-588)4148337-6 gnd rswk-swf Folsäure (DE-588)4121288-5 gnd rswk-swf Folate (DE-588)4154952-1 gnd rswk-swf Chemotherapie (DE-588)4127083-6 gnd rswk-swf Cotrimoxazol (DE-588)4148337-6 s Chemotherapie (DE-588)4127083-6 s DE-604 Folsäure (DE-588)4121288-5 s Folate (DE-588)4154952-1 s Hitchings, George H. 1905-1998 Sonstige (DE-588)110178602 oth Acar, Jacques F. 1931-2020 Sonstige (DE-588)171944666 oth Handbook of experimental pharmacology 64 (DE-604)BV002390716 64 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000035270&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis
spellingShingle	Inhibition of folate metabolism in chemotherapy the origins and uses of co-trimoxazole Handbook of experimental pharmacology Folic Acid cabt Antimetabolites cabt Sulfamethoxazole cabt Pharmacodynamics cabt Trimethoprim cabt Antibiotica gtt Antifoliques Cotrimoxazole - Effets physiologiques Farmacodynamica gtt Foliumzuur gtt Inhibitie gtt Stofwisseling gtt Sulfonamiden gtt Trimethoprim gtt Co-trimoxazole Physiological effect Folic Acid metabolism Folic acid Antagonists Sulfamethoxazole pharmacology Trimethoprim pharmacology Cotrimoxazol (DE-588)4148337-6 gnd Folsäure (DE-588)4121288-5 gnd Folate (DE-588)4154952-1 gnd Chemotherapie (DE-588)4127083-6 gnd
subject_GND	(DE-588)4148337-6 (DE-588)4121288-5 (DE-588)4154952-1 (DE-588)4127083-6
title	Inhibition of folate metabolism in chemotherapy the origins and uses of co-trimoxazole
title_auth	Inhibition of folate metabolism in chemotherapy the origins and uses of co-trimoxazole
title_exact_search	Inhibition of folate metabolism in chemotherapy the origins and uses of co-trimoxazole
title_full	Inhibition of folate metabolism in chemotherapy the origins and uses of co-trimoxazole contributors J. F. Acar ... Ed. G. H. Hitchings
title_fullStr	Inhibition of folate metabolism in chemotherapy the origins and uses of co-trimoxazole contributors J. F. Acar ... Ed. G. H. Hitchings
title_full_unstemmed	Inhibition of folate metabolism in chemotherapy the origins and uses of co-trimoxazole contributors J. F. Acar ... Ed. G. H. Hitchings
title_short	Inhibition of folate metabolism in chemotherapy
title_sort	inhibition of folate metabolism in chemotherapy the origins and uses of co trimoxazole
title_sub	the origins and uses of co-trimoxazole
topic	Folic Acid cabt Antimetabolites cabt Sulfamethoxazole cabt Pharmacodynamics cabt Trimethoprim cabt Antibiotica gtt Antifoliques Cotrimoxazole - Effets physiologiques Farmacodynamica gtt Foliumzuur gtt Inhibitie gtt Stofwisseling gtt Sulfonamiden gtt Trimethoprim gtt Co-trimoxazole Physiological effect Folic Acid metabolism Folic acid Antagonists Sulfamethoxazole pharmacology Trimethoprim pharmacology Cotrimoxazol (DE-588)4148337-6 gnd Folsäure (DE-588)4121288-5 gnd Folate (DE-588)4154952-1 gnd Chemotherapie (DE-588)4127083-6 gnd
topic_facet	Folic Acid Antimetabolites Sulfamethoxazole Pharmacodynamics Trimethoprim Antibiotica Antifoliques Cotrimoxazole - Effets physiologiques Farmacodynamica Foliumzuur Inhibitie Stofwisseling Sulfonamiden Co-trimoxazole Physiological effect Folic Acid metabolism Folic acid Antagonists Sulfamethoxazole pharmacology Trimethoprim pharmacology Cotrimoxazol Folsäure Folate Chemotherapie
url	http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000035270&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA
volume_link	(DE-604)BV002390716
work_keys_str_mv	AT hitchingsgeorgeh inhibitionoffolatemetabolisminchemotherapytheoriginsandusesofcotrimoxazole AT acarjacquesf inhibitionoffolatemetabolisminchemotherapytheoriginsandusesofcotrimoxazole

Holdings

There is no print copy available.

Interlibrary loan Place Request Caution: Not in THWS collection! Indexes

MARC

Record in the Search Index

There is no print copy available.

Similar Items